Announced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving a 44% cumulative MMR rate by 12 weeks in response-evaluable patients.

Advanced trials of ELVN-002, including activating the first site to evaluate ELVN-002 in combination with trastuzumab in patients with HER2+ cancers.

Entered into a securities purchase agreement for a private investment in public equity (PIPE) financing resulting in gross proceeds of $90 million, extending cash runway into late 2026.

Cash, cash equivalents and marketable securities totaled $320.5 million as of March 31, 2024.